Clinical References: Who Might Be Eligible for Retatrutide
While Bridge and his colleagues may have solved the supply bottleneck, Glyteine is still a premium-priced ingredient
Effects of ()-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinsons disease treated with l-DOPA
JCI Insight 8:e170671 Delvadia P, Dhote V, Mandloi AS et al (2025) Dual GLP-1 and GIP agonist Tirzepatide exerted neuroprotective action in a parkinsons disease rat model
47, n o 6, 378384 (ISSN 0301-4800 et 1881-7742, DOI 10.3177/jnsv.47.378, lire en ligne, consult le

RESEARCH AREAS Estrogen-related receptor alpha (ERR) agonism and receptor binding characterization Transcriptional regulation of mitochondrial biogenesis pathways (e.g., PGC-1 coactivation networks) Oxidative phosphorylation and fatty-acid oxidation gene-expression signaling Cellular energy-metabolism and substrate-utilization pathway modeling WHAT RESEARCHERS LOOK AT Receptor-binding and reporter-gene assays measuring ERR isoform engagement Dose-response transcriptional profiling of metabolic target genes in cell culture Mitochondrial density and respiration assays in isolated model systems Pathway-selectivity and off-target screening across nuclear-receptor panels QUICK SPECS Form: Capsule not for ingestion Net per capsule: 100mcg Count: 100 capsules per bottle Purity: 98% (HPLC) Identity: Confirmed by HPLC/MS Storage: Store sealed, cool, dry, protected from light IDENTITY BASICS Type: Synthetic small-molecule ERR agonist (non-peptide) Molecular formula: CHNO Molecular weight: ~445.5 g/mol CAS: 2231747-31-0 SELECTED RESEARCH PubChem: SLU-PP-332 compound record PubMed: SLU-PP-332 literature index PubMed: ERR agonist research PubMed: ERR/mitochondrial biogenesis signaling DISCLAIMER For laboratory and in vitro research use only
